PMID: 16502484Feb 28, 2006Paper

Further increase of vancomycin-resistant Enterococcus faecium, amikacin- and fluoroquinolone-resistant Klebsiella pneumoniae, and imipenem-resistant Acinetobacter spp. in Korea: 2003 KONSAR surveillance

Yonsei Medical Journal
Kyungwon Lee KONSAR group

Abstract

Monitoring temporal trends of antimicrobial resistance can provide useful information for the empirical selection of antimicrobial agents to treat infected patients and for the control of nosocomial infections. In this study, we analyzed antimicrobial resistance of clinically relevant bacteria in 2003 at Korean hospitals and at a commercial laboratory. The following organism-antimicrobial agent resistance combinations were very prevalent: oxacillin-resistant Staphylococcus aureus (68%), expanded-spectrum cephalosporin-resistant Klebsiella pneumoniae (25%), and fluoroquinolone-resistant Escherichia coli (33%), Acinetobacter spp. (58%), and Pseudomonas aeruginosa (40%). Moreover, gradual increases in vancomycin-resistant Enterococcus faecium (20%), cefoxitin-resistant E. coli (10%) and K. pneumoniae (23%), and imipenem-resistant P. aeruginosa (20%) and Acinetobacter spp. (13%) were also observed. The resistance rates of Acinetobacter spp. to most antimicrobial agents at hospitals and at the commercial laboratory were similar. Among the Acinetobacter spp. isolated at a tertiary-care hospital, 46.2% were multidrug-resistant to 9-12 of 13 antimicrobial agents, and 18.3% were panresistant. The exclusion of duplicate isolates at a ter...Continue Reading

References

Jan 1, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J M Stelling, T F O'Brien
Mar 31, 1999·Yonsei Medical Journal·Y ChongJ H Shin
Sep 7, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D F SahmG Piazza
Nov 24, 1999·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·K Yasunaka, K Kono
Oct 26, 2000·Current Opinion in Microbiology·D M Livermore, N Woodford
Jul 10, 2001·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·R BaxA White
Dec 26, 2001·The Journal of Antimicrobial Chemotherapy·A K Morris, R G Masterton
Jul 4, 2002·Emerging Infectious Diseases·Scott K FridkinUNKNOWN Intensive Care Antimicrobial Resistance Epidemiology Project Hospitals
May 15, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Carl UrbanJames J Rahal
Jul 3, 2003·The Journal of Antimicrobial Chemotherapy·Gunnar KahlmeterAlkiviadis Vatopoulos
Sep 16, 2003·Emerging Infectious Diseases·Adriana O ReisAna C Gales
Oct 2, 2003·Emerging Infectious Diseases·Chris A Van BenedenCynthia G Whitney
Dec 25, 2003·Antimicrobial Agents and Chemotherapy·R Bonnet
Mar 17, 2004·Diagnostic Microbiology and Infectious Disease·Tsai-Ling LauderdaleUNKNOWN TSAR Participating Hospitals
Apr 3, 2004·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·G CornagliaUNKNOWN ESCMID Study Group for Antimicrobial Resistance Surveillance
Apr 15, 2004·Journal of Korean Medical Science·Tae-Min KimMun-Gan Rhyu
May 25, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jae-Hoon SongUNKNOWN Asian Network for Surveillance of Resistant Pathogens Study Group
Jun 12, 2004·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·I A Critchley, J A Karlowsky
Jul 3, 2004·The Journal of Antimicrobial Chemotherapy·Richard Wise
Sep 3, 2004·Yonsei Medical Journal·Kyungwon LeeUNKNOWN Korean Natiowide Surveillance of Antimicrobial Resistance Group
Oct 23, 2004·Emerging Infectious Diseases·Edine W TiemersmaUNKNOWN European Antimicrobial Resistance Surveillance System Participants
Jan 7, 2005·Journal of Clinical Microbiology·Adam N TreitmanGary A Noskin
Feb 12, 2005·Emerging Infectious Diseases·Aharon AbboYehuda Carmeli
Mar 16, 2005·Diagnostic Microbiology and Infectious Disease·Robertino M MeraAnthony R White
Apr 28, 2005·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Akiyoshi TsujiSachiko Goto

❮ Previous
Next ❯

Citations

Dec 7, 2010·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Sun Hee ParkJin-Hong Yoo
Jul 25, 2007·Antimicrobial Agents and Chemotherapy·Federico PerezRobert A Bonomo
Oct 8, 2013·Diagnostic Microbiology and Infectious Disease·Mi Hyun BaeMi-Na Kim
Dec 18, 2008·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Hiroshi Koganemaru, Shigemi Hitomi
May 28, 2008·American Journal of Infection Control·Evelina N Lagamayo
Jun 14, 2015·International Journal of Antimicrobial Agents·Matthew E FalagasNikolaos S Roussos

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.